Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) shares advanced 8.63% in last trading session and ended the day at $12.72. AMPH Gross Margin is 24.40% and its has a return on assets of -3.20%. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) quarterly performance is -9.59%.
Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.19, $0.23 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $76.9 million versus the consensus estimate of $64.48 million.
Lululemon Athletica Inc. (NASDAQ:LULU) ended the last trading day at $62.98. Company weekly volatility is calculated as 2.15% and price to cash ratio as 21.63. Lululemon Athletica Inc. (NASDAQ:LULU) showed a weekly performance of 1.22%.
lululemon athletica inc. (NASDAQ:LULU) announced that its financial results for the fourth quarter and fiscal year 2015 will be released Wednesday, March 30, 2016. The company will host a conference call at 9:00 a.m. Eastern time to discuss the financial results.
On 15 March, Lionbridge Technologies Inc. (NASDAQ:LIOX) shares moved down -2.81% and was closed at $4.85. LIOX EPS growth in last 5 year was 68.30%. Lionbridge Technologies Inc. (NASDAQ:LIOX) year to date (YTD) performance is -1.22%.
Lionbridge Technologies, Inc. (NASDAQ:LIOX), announced the Lionbridge connector for Episerver Digital Experience Cloud. By seamlessly connecting the Lionbridge translation platform with Episerver’s digital marketing, content and digital commerce solutions, marketers are now able to create, store and manage multilingual content from within their working environment, regardless of whether they are running in the cloud or on premise.
VIVUS Inc. (NASDAQ:VVUS) shares moved down -4.76% in last trading session and ended the day at $1.20. VVUS Gross Margin is 64.20% and its has a return on assets of -30.10%. VIVUS Inc. (NASDAQ:VVUS) quarterly performance is 20.00%.
On 9 March, Vivus Inc. (NASDAQ:VVUS) reported a loss of $12.2 million in its fourth quarter. The Mountain View, California-based company said it had a loss of 12 cents per share. The biopharmaceutical company posted revenue of $15.3 million in the period. For the year, the company reported that its loss widened to $93.1 million, or 90 cents per share. Revenue was reported as $95.4 million.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) caters to the Healthcare space. Its weekly performance is -11.77%. On the last day of trading company shares ended up at $7.87.
Adaptimmune Therapeutics plc (NASDAQ:ADAP), announced that James Noble, Chief Executive Officer of Adaptimmune, presented at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7th at 4:40 PM (9:40 PM GMT).
Leave a Reply